Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m

Director Lu Hongbo reported purchasing shares of Zenas BioPharma Inc (NASDAQ:ZBIO) in two transactions, totaling $6,000,031. The stock, currently trading at $27.78, has seen remarkable growth with a 216% gain year-to-date, according to InvestingPro data.

The purchases occurred on September 13, 2024, and October 7, 2025, with prices ranging from $17.0 to $19.0. On September 13, Lu acquired 58,823 shares at $17.0 per share. Subsequently, on October 7, Lu Hongbo bought 263,160 shares at $19.0 each. The stock is currently trading near its 52-week high, with analyst targets ranging from $24 to $45. InvestingPro offers 11 additional investment insights for ZBIO.

In other recent news, Zenas Biopharma has secured a significant licensing agreement with InnoCare Pharma, valued at over $2 billion. This deal grants Zenas the global rights to develop and commercialize three autoimmune product candidates, including orelabrutinib, a BTK inhibitor currently in Phase 3 development for multiple sclerosis. As part of the agreement, Zenas will pay InnoCare up to $100 million in cash and issue up to 7 million shares of its common stock. H.C. Wainwright has reiterated a Buy rating on Zenas Biopharma, citing the pipeline expansion as a positive development. Additionally, Zenas Biopharma has gained rights to a novel oral IL-17AA/AF inhibitor and an oral brain-penetrant TYK2 inhibitor. In other company news, Zeta Network Group announced a strategic partnership with SOLV Foundation to enhance its Bitcoin-centric financial initiatives. This partnership involves leveraging SOLV’s platform, which holds $2.5 billion in total value locked, to optimize ZNB’s Bitcoin holdings. The agreement ensures transparency and institutional-grade auditability through a regulated third-party custodian.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.